deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03252093

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

A Randomized, Placebo-controlled, Double Blind Evaluation of the Safety and Efficacy of Angiotensin 1-7 (Ang-(1-7)) to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery.

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Cognitive Impairment Coronary Artery Bypass Surgery
Interventions Angiotensin-(1-7) Placebo for Angiotensin-(1-7)
Updated 10 times since 2017 Last updated: May 29, 2025 Started: Jul 20, 2017 Primary completion: Nov 15, 2022 Completion: Nov 15, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding ended

Other terminated trials from National Heart, Lung, and Blood Institute (NHLBI)

See all terminations from National Heart, Lung, and Blood Institute (NHLBI)

Other Cognitive Impairment trials with similar outcome

Browse all Cognitive Impairment trials

This PHASE2 trial investigates Cognitive Impairment and Coronary Artery Bypass Surgery and is currently terminated or withdrawn. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotRecruiting~Jan 2019 – ~May 2019 · 4 months · monthly snapshotRecruiting~May 2019 – ~Dec 2020 · 19 months · monthly snapshotTerminated~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotSuspended~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshotSuspended~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotSuspended~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotSuspended~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotSuspended~Jul 2025 – present · 14 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Jul 2025 — Present [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Sep 2024 — Jul 2025 [monthly]

    Suspended PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE2

  4. Jun 2022 — Jul 2024 [monthly]

    Suspended PHASE2

  5. Jan 2021 — Jun 2022 [monthly]

    Suspended PHASE2

▶ Show 5 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Suspended PHASE2

    Status: Terminated → Suspended

  2. May 2019 — Dec 2020 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  3. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE2

  4. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  5. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Suburban Hospital
  • University of Arizona
Data source: University of Arizona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations